StockData
Bioventus Inc. logo

Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.62+0.02 (+0.19%)

Close on Nov 18, 2026Market cap $893.06MP/E 13.8Yield –

Bioventus gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Bioventus's gross profit for the twelve months ending Jun 27, 2026 was $399.45M, up 4.7% year over year. For fiscal 2025 it was $388.16M, down 0.0% from the year before. The highest annual figure on record is $388.23M in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$388.16M-0.0%
FY2024Dec 31, 2024$388.23M+18.3%
FY2023Dec 31, 2023$328.19M-0.9%
FY2022Dec 31, 2022$331.08M+9.4%
FY2021Dec 31, 2021$302.71M+29.6%
FY2020Dec 31, 2020$233.52M-6.3%
FY2019Dec 31, 2019$249.21M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$105.67M+3.5%
Q1 FY2026Mar 28, 2026$90.77M+9.3%
Q4 FY2025Dec 31, 2025$108.78M+6.0%
Q3 FY2025Sep 27, 2025$94.23M+0.7%
Q2 FY2025Jun 28, 2025$102.09M-1.5%
Q1 FY2025Mar 29, 2025$83.06M-6.0%
Q4 FY2024Dec 31, 2024$102.66M+19.0%
Q3 FY2024Sep 28, 2024$93.55M+18.6%
Q2 FY2024Jun 29, 2024$103.64M+16.3%
Q1 FY2024Mar 30, 2024$88.38M+19.6%
Q4 FY2023Dec 31, 2023$86.30M+16.3%
Q3 FY2023Sep 30, 2023$78.85M-6.7%
Q2 FY2023Jul 1, 2023$89.12M-7.8%
Q1 FY2023Apr 1, 2023$73.92M-2.4%
Q4 FY2022Dec 31, 2022$74.19M-15.5%
Q3 FY2022Oct 1, 2022$84.54M+6.9%
Q2 FY2022Jul 2, 2022$96.65M+26.7%
Q1 FY2022Apr 2, 2022$75.70M+27.1%
Q4 FY2021Dec 31, 2021$87.77M+19.5%
Q3 FY2021Oct 2, 2021$79.07M+26.6%
Q2 FY2021Jul 3, 2021$76.31M+89.1%
Q1 FY2021Apr 3, 2021$59.56M+4.1%
Q4 FY2020Dec 31, 2020$73.47M–
Q3 FY2020Sep 26, 2020$62.46M–
Q2 FY2020Jun 27, 2020$40.35M–
Q1 FY2020Mar 28, 2020$57.24M–

More Bioventus figures

See a number that looks wrong?